TNXP Earnings & Financial Statements
Tonix Pharmaceuticals Holding Corp.
$6.40
+$0.27(+4.40%)
46
Overall
60
Value
36
Tech
44
Quality
Market Cap
$109.77M
Volume
1.39M
52W Range
$7.09 - $20.69
Target Price
$42.40
TNXP earnings and financial statements: Tonix Pharmaceuticals Holding Corp.'s income statement, balance sheet and cash flow statement, annual and quarterly.
TNXP Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $13.11M | $10.09M | $7.77M | - | - |
| Cost of revenue | $6.64M | $7.76M | $4.74M | - | - |
| Operating income | -$125.70M | -$136.70M | -$118.38M | -$112.09M | -$92.31M |
| EBITDA | -$120.11M | -$124.54M | -$112.37M | -$110.84M | -$92.26M |
| Net income | -$124.02M | -$130.04M | -$116.66M | -$110.22M | -$92.29M |
| EPS (diluted) | $-14.57 | $-176.60 | $-21888.00 | $-65400.00 | $-166400.00 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $277.17M | $162.89M | $154.46M | $225.69M | $240.90M |
| Total liabilities | $32.02M | $23.33M | $48.93M | $18.51M | $22.18M |
| Shareholders’ equity | $245.15M | $139.56M | $105.53M | $207.18M | $218.72M |
| Cash and equivalents | $207.64M | $98.78M | $24.95M | $120.23M | $178.66M |
| Long-term debt | $1.18M | $5.03M | $7.19M | $328.0K | $467.0K |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$99.84M | -$60.92M | -$102.00M | -$98.05M | -$75.56M |
| Capital expenditure | -$3.37M | -$120.0K | -$7.89M | -$48.15M | -$35.31M |
| Free cash flow | -$103.21M | -$61.05M | -$109.90M | -$146.20M | -$110.86M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | TNXP | $6.40 | +4.4% | 1.39M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Tonix Pharmaceuticals Holding Corp. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW